Oriana Damas

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Lisa Malter, MD, FACG, is a Professor of Medicine at the NYU School of Medicine, the Director of Education for the NYU IBD Center and Director of the Inflammatory Bowel Disease Clinic at the Bellevue Hospital Center in New York City. Board-certified in Gastroenterology, Dr. Malter’s patient practice is focused primarily on inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, and she has pioneered access to care for the underserved patient population at Bellevue. Dr. Malter’s academic interests include the study of inflammatory bowel disease, patient safety, and fellowship education. Dr. Malter teaches at the NYU Grossman School of Medicine and has published in Inflammatory Bowel Diseases,  The American Journal of Gastroenterology and CC360. She is a member of ACG, AGA, and the Crohn's and Colitis Foundation. She serves as the Editor of the ACG Universe, is a member of the ACG Training Committee, the ACG Education Task Force, and is a faculty advisor for the Crohn's &Colitis Foundation's Greater New York Fellows’ Education Committee. She created and created and directs IBD 101, a first year fellows course on IBD, in collaboration with NYU and the ACG.  Dr. Malter received her medical degree from Rosalind Franklin University/Chicago Medical School, completed her internal medicine internship and residency at The Mount Sinai Hospital in New York, and went on to complete a Gastroenterology fellowship at NYU Langone Medical Center.

Lisa Malter, MD, FACG, is a Professor of Medicine at the NYU School of Medicine, the Director of Education for the NYU IBD Center and Director of the Inflammatory Bowel Disease Clinic at the Bellevue Hospital Center in New York City. Board-certified in Gastroenterology, Dr. Malter’s patient practice is focused primarily on inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, and she has pioneered access to care for the underserved patient population at Bellevue. Dr. Malter’s academic interests include the study of inflammatory bowel disease, patient safety, and fellowship education. Dr. Malter teaches at the NYU Grossman School of Medicine and has published in Inflammatory Bowel Diseases,  The American Journal of Gastroenterology and CC360. She is a member of ACG, AGA, and the Crohn's and Colitis Foundation. She serves as the Editor of the ACG Universe, is a member of the ACG Training Committee, the ACG Education Task Force, and is a faculty advisor for the Crohn's &Colitis Foundation's Greater New York Fellows’ Education Committee. She created and created and directs IBD 101, a first year fellows course on IBD, in collaboration with NYU and the ACG.  Dr. Malter received her medical degree from Rosalind Franklin University/Chicago Medical School, completed her internal medicine internship and residency at The Mount Sinai Hospital in New York, and went on to complete a Gastroenterology fellowship at NYU Langone Medical Center.

David Choi completed his Doctor of Pharmacy degree at the University of Colorado School of Pharmacy. He went on to complete his PGY1 Pharmacy Residency and PGY2 Ambulatory residency at The Johns Hopkins Hospital. He is currently an Associate Director at University of Chicago Medicine Inflammatory Bowel Disease Center. He is very excited about advocating for increased pharmacists’ role in gastroenterology/hepatology as well as importance for patient advocacy in receiving the care they require. He feels passionately about treat to target to improve patient care and research related to improving patient outcomes.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Dr. Sara Horst MD, MPH, FACG, AGAF is a Professor in the division of Gastroenterology, Hepatology, & Nutrition at Vanderbilt University Medical Center. Dr. Horst completed her medical school and residency training at The Ohio State University and then went to Vanderbilt University Medical Center for Gastroenterology Fellowship and to obtain her Masters of Public Health. She joined the faculty at Vanderbilt University Medical Center in 2011. She is involved in clinical care of complex IBD care, complex amyloid care, clinical research, and teaching and mentoring medical students and housestaff. She is the medical director for VUMC Specialty Pharmacy, VUMC Telehealth director, and VUMC Associate Vice Chair of Clinical Affairs for Dept of Medicine. Her research interests involve enhancing EHR efficiencies in the care of IBD, telehealth in IBD, and medication adherence in IBD. She has extensively published in peer reviewed journals. She is also involved in clinical care improvement as an EPIC Physician Builder and is on the National EPIC GI Steering Board. She is an associate editor for American Journal of Gastroenterology.

Jami Kinnucan, MD, is an inflammatory bowel disease (IBD) specialist who joined the Mayo Clinic Florida practice in January 2021 as an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology. She currently serves as the Clinical Practice Chair for the Division of Gastroenterology & Hepatology, Associate Chair for Digital Transformation and Practice Integration for the Department of Medicine and Medical Director for Plummer Chart Ambulatory Communication Solutions team. She is also the Director of the IBD Intestinal Ultrasound Program at Mayo Clinic Florida. She has been recognized as a fellow of the American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), and Crohn's and Colitis Foundation. She is a former member of the ACG Board of Governors for the state of Michigan and the ACG Women in Gastroenterology Committee. She is active in the Crohn’s and Colitis Foundation and previous Co-Chair for the Women in IBD Task Force and prior member of the Government and Industry Affairs Committee for the National Scientific Advisory Committee. Dr. Kinnucan is the co-founder of the Michigan GI Society in 2020 and, most recently, co-founded the Florida Women in GI (2022) and Gastro Digital Health (2024) She serves as Associate Editor for the Crohn’s and Colitis 360 Journal. She is actively involved with research looking at the impact of cannabis in IBD and received a 2024 Mayo Clinic STARDOM award to evaluate the use of virtual reality on the impact of pain in patients with abdominal pain and Crohn’s disease.

Dr. Ryan Ungaro is an Assistant Professor of Medicine in the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai. Dr. Ungaro received his undergraduate degree from Wesleyan University and his medical degree from the Icahn School of Medicine at Mount Sinai where he graduated Alpha Omega Alpha with Distinction in Research. He completed his internal medicine training and served as chief resident at the Mount Sinai Medical Center then went on to complete fellowship training in gastroenterology at the Mount Sinai Medical Center and served as chief gastroenterology fellow. Dr. Ungaro received training in translational inflammatory bowel disease (IBD) research as a Howard Hughes Medical Institute Research Fellow and completed a Masters in Biostatistics and Clinical Research Methods at Columbia University Mailman School of Public Health.

Dr. Ungaro specializes in the care of patients with ulcerative colitis and Crohn's disease. He is Director of the Comprehensive Care for the Recently Diagnosed IBD Patient (COMPASS-IBD) Program at the Mount Sinai IBD Clinical Center. This program provides interdisciplinary care for recently diagnosed inflammatory bowel disease (IBD) patients. His research focuses on understanding early IBD including the impact of early intervention on IBD outcomes and precision medicine approaches to improve risk stratification and optimization of therapy for recently diagnosed IBD patients. His work is supported by an NIH K23 Career Development Award. He is also co-founder of the SECURE-IBD Registry which aims to understand the impact of COVID-19 on IBD patients.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.